Clinical Trial: GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic Protoporphyria

U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT06971900) titled 'GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic Protoporphyria' on April 03.

Brief Summary: A Phase 2a study of PORT-77 in adults with erythropoietic protoporphyria (EPP)

Study Start Date: April 04

Study Type: INTERVENTIONAL

Condition: Erythropoietic Protoporphyria (EPP)

Intervention: DRUG: PORT-77

Active oral dose form

DRUG: Placebo

Matching inactive oral dose form

Recruitment Status: ENROLLING_BY_INVITATION

Sponsor: Portal Therapeutics, Inc.

Disclaimer: Curated by HT Syndication....